Qiagen N.V.

QIAGEN NV's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, QIAGEN NV has 206.50M shares outstanding.

As of June 30, 2026, QIAGEN NV maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 48.95, indicating elevated leverage, while an interest coverage ratio of 16.42 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, QIAGEN NV posted a return on equity (ROE) of 11.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.97 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.99, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.93, useful for judging operating efficiency across full business cycles. The company generates approximately 6.46M in revenue per employee across its workforce of 5,681.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.63 indicates how many times QIAGEN NV sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, QIAGEN NV recorded 917.49M in income tax expense. That works out to an effective tax rate of 11.37, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.07B, leaving 7.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 3, 2026, QIAGEN NV's stock has declined approximately 23.22% over the past 52 weeks.

Over the twelve months ended June 30, 2026, QIAGEN NV generated 36.70B in revenue and converted that into 7.15B in net income, yielding earnings per share of 34.38. EBITDA reached 11.31B, while operating income came in at 9.03B.

As of June 30, 2026, QIAGEN NV holds 13.86B in cash and equivalents against 28.72B in total debt, resulting in a net debt position of 15.29B. Total book value stands at 58.67B, with working capital of 18.79B providing operational flexibility.

QIAGEN NV produced 11.43B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.74B in capital expenditures, free cash flow totaled 7.70B - equivalent to 37.30 per share.

Over the twelve months ended June 30, 2026, QIAGEN NV posted a gross margin of 62.20, reflecting its pricing power and cost economics. The operating margin of 24.60 and net profit margin of 19.49 provide insight into operational efficiency.

QIAGEN NV's most recent stock split took place on January 8, 2026 with a 20:19 split ratio.